Palatin Technologies (PTN) Tops Q1 EPS by 2c

Go back to Palatin Technologies (PTN) Tops Q1 EPS by 2c

Palatin Technologies (PTN) Commences Enrollment in BMT Phase 3s; Noble Financial Affirms at 'Buy'

February 17, 2015 2:14 PM EST

Noble Financial affirms Palatin Technologies (AMEX: PTN) at Buy with a price target of $3.50 following Q1 results and outlook last Friday.

Analyst Rahul Jasuja offered the following observations and commentary on Palatin:

Both Phase 3 US registration trials (Reconnect Study) with bremelanotide (BMT) for female sexual dysfunction (FSD) enrolling;... More

Palatin (PTN) Outpaces Q2 Ests on BMT Program Milestone; Roth Capital Affirms at 'Buy'

February 13, 2015 2:40 PM EST

Roth Capital affirms Palatin Technologies (AMEX: PTN) at Buy with a price target of $4 following FQ215 results reported earlier this morning.

Analyst Joseph Pantginis noted that Palatin's Q2 EPS of $0.03 and revenue of $8 million compared with his EPS estimate of break even and... More